Third Harmonic halting non-THB335 research, reducing workforce by 50%
In parallel with THB335 Phase 2 readiness activities, Third Harmonic Bio (THRD) is initiating a process to identify opportunities to maximize ...
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty
Bio (NASDAQ:THRD) stock rating was downgraded by Morgan Stanley (NYSE:MS) from Overweight to Equalweight, accompanied by a significant reduction in the price target to $5.00 from the previous $20.00.
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update
THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...
Wall Street Journal25d
Third Harmonic Bio Inc.
1 Day THRD 1.94% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 1527.34% ...
Nasdaq2y
Third Harmonic Bio, Inc. Common Stock (THRD) Institutional Holdings
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Investing20h
Third Harmonic Bio stock tumbles after clinical trial results
The full results of the Phase 1 trial will be presented at the AAAAI/WAO Joint Congress on Sunday, March 2, 2025. Meanwhile, Third Harmonic Bio plans to proceed with THB335 development activities ...